Search company, investor...



Incubator/Accelerator | Alive

About M3datek

M3datek is developing 3D bioprinters for tissue repair and regeneration.

Headquarters Location

Parco Area delle Scienze 27/A



Missing: M3datek's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: M3datek's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing M3datek

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

M3datek is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

M3datek Frequently Asked Questions (FAQ)

  • Where is M3datek's headquarters?

    M3datek's headquarters is located at Parco Area delle Scienze 27/A, Parma.

  • What is M3datek's latest funding round?

    M3datek's latest funding round is Incubator/Accelerator.

  • Who are the investors of M3datek?

    Investors of M3datek include Impact Hub Milano.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.